Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Garland Lee

Physician Assistant, Medical West Orange, NJ Physician Assistant

NPI 1124456561 CMS profile 11110715

347 Mount Pleasant Ave, Suite 205, West Orange, NJ 07052

Open in the dashboard

General payments

$10,342

504 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Garland Lee of West Orange, NJ is reported in the CMS Open Payments database as having received $10,342 across 504 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,577 64
2024 General $2,652 110
2023 General $1,958 99
2022 General $1,815 104
2021 General $2,341 127

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Garland Lee
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Garland Lee were reported at $1,577. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Garland Lee Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,341 $156 $41–$563 $132
2022 $1,815 $185 $55–$649 $149
2023 $1,958 $199 $58–$717 $160
2024 $2,652 $206 $62–$740 $164
2025 $1,577 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $1,745 114 payments
  2. Janssen Biotech, Inc. $1,493 68 payments
  3. Pfizer Inc. $779 38 payments
  4. Novartis Pharmaceuticals Corporation $657 33 payments
  5. Dermavant Sciences, Inc. $638 17 payments
  6. Amgen Inc. $608 24 payments
  7. E.R. Squibb & Sons, L.L.C. $552 31 payments
  8. Galderma Laboratories, L.P. $500 16 payments
  9. Arcutis Biotherapeutics, Inc. $463 16 payments
  10. LEO Pharma Inc. $457 26 payments
  11. Other $2,450 121 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,039 500 payments
  2. Education $302 4 payments
Products named General payments · program years 2021–2025
  1. TREMFYA $1,492 57 payments
  2. SKYRIZI $1,168 73 payments
  3. VTAMA $698 20 payments
  4. EUCRISA $646 32 payments
  5. Otezla $608 24 payments
  6. SOTYKTU $552 31 payments
  7. CIBINQO $452 23 payments
  8. RINVOQ $451 29 payments
  9. DUPIXENT $412 19 payments
  10. COSENTYX $395 20 payments
  11. Other $3,973 229 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 18 billing codes

Paid by Medicare

$7,357

Medicare's payments for the services billed

Medicare patients

15

Average age 72

Services billed

159

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Chronic kidney disease 0%
COPD 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VTAMA
  • Dermavant Sciences, Inc. $599
$599 — —
TREMFYA
  • Janssen Biotech, Inc. $354
  • Janssen Scientific Affairs, LLC $92
$446 — —
SKYRIZI
  • AbbVie, Inc. $315
$315 — —
ADBRY
  • LEO Pharma Inc. $172
$172 — —
COSENTYX
  • Novartis Pharmaceuticals Corporation $161
$161 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

504 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record